IP Library Granted Patent US 10,017,561
Granted Patent B2
US 10,017,561 · App. 14/970,244 · Granted Jul 10, 2018

Neutralizing molecules to influenza viruses

Inventors: Lawrence Horowitz (Atherton, CA); Ramesh Bhatt (Belmont, CA); Arun Kashyap (Newark, CA)
Assignee: I2 PHARMACEUTICALS, INC.
C07K16/1018A61K9/0043A61K9/0053A61K39/145C12N7/00A61K2039/505A61K2039/5252A61K2039/5254A61K2039/54A61K2039/543A61K2039/55C07K2317/21C07K2317/33C07K2317/56C07K2317/565C07K2317/567C07K2317/76C07K2317/92C12N2760/16134
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,017,561
App. No.
14/970,244
Granted
Jul 10, 2018
Kind
B2
Abstract

The present invention concerns methods and means for identifying, producing, and engineering neutralizing antibodies against influenza A viruses, and to the neutralizing antibodies produced. In particular, the invention concerns neutralizing antibodies against various influenza A virus subtypes, and methods and means for making such antibodies.

Claims (13)

1. An antibody that binds an influenza virus comprising a heavy chain, the heavy chain comprising the hypervariable region sequences of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9; and (b) a light chain comprising the hypervariable region sequences of SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15; wherein the antibody (i) neutralizes more than one subtype or more than one isolate of an influenza A virus, (ii) binds to a hemagglutinin antigen (HA) of the virus, and (iii) inhibits hemagglutination.

2. The antibody of claim 1 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 1.

3. The antibody of claim 2 ,

wherein the light chain comprises the amino acid sequence of SEQ ID NO:5.

4. The antibody of claim 1 ,

which prevents the globular head region of the influenza A virus from binding and attaching to the surface of a cell.

5. A composition comprising the antibody of claim 1 .

6. The antibody of claim 1 , wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 1 and wherein the light chain comprises the amino acid sequence of SEQ ID NO: 5.

7. The antibody of claim 6 , which binds to an H1 HA antigen, and optionally binds to at least one additional HA antigen, wherein the additional HA antigen is selected from an H3 HA antigen and an H9 HA antigen.

8. The antibody of claim 7 , wherein the H1 HA is from a New Caledonia/20/99 isolate or a Solomon Islands/3/06 isolate of the H1 virus.

9. The antibody of claim 7 , wherein the H3 HA is from a Wisconsin/67/05 isolate or a Hong Kong/68 isolate of the H3 virus.

10. The antibody of claim 7 , wherein the H9 HA is from, a Hong Kong/1073/99 isolate of the H9 virus.

11. The antibody of claim 1 , wherein at least one of the influenza virus isolates has the ability to infect humans.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: HOROWITZ, LAWRENCE; BHATT, RAMESH; KASHYAP, ARUN
To: SEA LANE BIOTECHNOLOGIES, LLC.
Reel/Frame 041151/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: SEA LANE BIOTECHNOLOGIES, LLC.
To: ALTUS BIOPHARMA INC.
Reel/Frame 041154/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: ALTUS BIOPHARMA INC.
To: I2 PHARMACEUTICALS, INC.
Reel/Frame 041154/0613 →
Continuity (4)
Continuation 13261004
Provisional Application 61228114 · Jul 23, 2009
Provisional Application 61177987 · May 13, 2009
Related Publication 20160096882A1 · Apr 7, 2016